As China biotech booms, Fidelity group rolls out $250M fund with a big focus on drug R&D
Eight Roads Ventures has finished mapping plans for a new, $250 million fund that is reserving a big chunk of cash for China’s booming …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
